Clinical trials: Imaging, Diagnostic
Pancreatic Cancer
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2*…
- Trial name
- NCT06129422
- Testing
- NMK89
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Nihon Medi-Physics Co., Ltd.
Coronary Artery Disease, Atherosclerosis
The Lipid-Rich Plaque Study
The purpose of this study is to enhance medical knowledge of the causes of future coronary problems. Many studies in patients who have already experienced a coronary problem point to the danger associated with plaques that are…
- Trial name
- LRP (NCT02033694)
- Testing
- NIRS-IVUS Imaging (TVC Imaging System)
- Where
- 41 sites in United States, Italy and 4 more
- Volunteers
- 1,563 people
- Sponsor
- Infraredx
Prostate Cancer
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Trial name
- NCT06122584
- Testing
- [18F]PSMA-1007
- Where
- 18 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Claustrophobia, Complication of Diagnostic Procedure
Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM
Annually, an estimated 700,000 patients do not complete their scheduled MRI scans because of claustrophobia or inability to hold still.
- Trial name
- NCT01563198
- Testing
- Comfort Talk®
- Where
- 4 sites in United States
- Volunteers
- 97,712 people
- Sponsor
- Hypnalgesics, LLC
Dental Caries
Post-Approval Clinical Study to Evaluate the Calcivis Caries Activity Imaging System
This is a prospective, multi-centre, post-approval clinical study to assess the safety and the performance of the Calcivis Caries Activity Imaging System in aiding the identification of active caries lesions on the occlusal…
- Trial name
- NCT02098304
- Testing
- Calcivis Caries Activity Imaging System
- Where
- 3 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Calcivis Ltd
Willing and Able Subjects for Ocular Imaging
Non-Invasive Imaging of the Human Eye
Evaluate the clinical information obtained from the use of the machines.
- Trial name
- NCT02432898
- Testing
- 3D OCT-1, 3D OCT-2000, DRI OCT-1
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Healthy Volunteers
A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults
This study is to see how well MSP-2020 attaches to specific targets in the brain called serotonin type 2A receptors (5-HT2AR). This study will also look at how much of the study drug (and its metabolite) is in the blood and how…
- Trial name
- NCT07329621
- Testing
- MSP-2020
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Breast Cancer
Micrima MARIA Data Collection for Machine Learning Study
The MARIA® breast imaging system is a CE-marked radiofrequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and cancerous tissues.
- Trial name
- NCT04894955
- Testing
- MARIA
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Micrima, Ltd.
Advanced PD-L1 Positive Malignancies
Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies
The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN3504. The secondary objectives of the study are: Study Part A only: To establish adequate mass dose and activity dose of…
- Trial name
- NCT03746704
- Testing
- 89Zr˗DFO˗REGN3504
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Regeneron Pharmaceuticals
Parkinson's Disease
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
REPAIR-PD is a single-center open label pilot, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been…
- Trial name
- REPAIR-PD (NCT03815916)
- Testing
- Gold Nanocrystals
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Clene Nanomedicine
Pain
A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients
This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of…
- Trial name
- NCT00610155
- Testing
- Pregabalin, Tramadol SR
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prostate Cancer
BR55 in Prostate Cancer: an Exploratory Clinical Trial
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging.
- Trial name
- NCT01253213
- Testing
- BR55
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Bracco Diagnostics, Inc
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Central Nervous System Diseases, Central Nervous System Neoplasms
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
This is a retrospective study to collect already existing data and images from patients ≥ 2 years of age who had MRI for CNS diseases with MultiHance administration at a standard 0.10 mmol/kg dose or the half dose of 0.05…
- Trial name
- NCT03147989
- Testing
- MultiHance
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Bracco Diagnostics, Inc
NSCLC
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and clinical patient outcome.
- Trial name
- PANU (NCT04276025)
- Testing
- Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
- Volunteers
- 2,000 people
- Sponsor
- Klinikum Bayreuth GmbH
Peripheral Artery Disease
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on the leg artery structure and physical activity in patients with atherosclerotic peripheral artery disease and leg pain from walking.
- Trial name
- NCT01731990
- Testing
- Canakinumab (ACZ885)
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
- Trial name
- NCT00557310
- Testing
- teriparatide
- Where
- 6 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Cancer Patients
Verification of Imaging System PCD-1000A
Scope Verification of technologies included in the PCD-1000A PET/CT imaging chain. Define and confirm all supported clinical protocols Evaluate performance
- Trial name
- NCT04024748
- Testing
- PET/CT imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Canon Medical Systems, USA
Multiple Sclerosis
ATX-MS-1467 in Multiple Sclerosis
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of…
- Trial name
- NCT01973491
- Testing
- ATX-MS-1467
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Heart Failure, Congestive
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126425
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.